---

Javeria Zaheer^1,2

¹Shalamar Medical and Dental College, Lahore, Pakistan

²Medical and Health Centre, University of Agriculture, Faisalabad, Pakistan

Corresponding Author Email: zjaveria25@gmail.com

DOI : https://doi.org/10.51470/APR.2025.04.01.26

Abstract

Keywords

Download this article as:

---

Introduction

Hypertension affects approximately 1.4 billion individuals globally and remains a major risk factor for cardiovascular diseases, which are now the leading cause of mortality worldwide [1]. A central pathological feature of hypertension is endothelial dysfunction, which is marked by impaired vasodilation, increased vasoconstriction, cellular proliferation, and a shift toward a proinflammatory and prothrombotic state [2]. This dysfunction contributes to the initiation and progression of vascular inflammation, vascular remodeling, and atherosclerosis. The vascular endothelium plays a pivotal role in regulating vascular homeostasis, primarily through the release of vasoactive substances—most notably nitric oxide (NO). NO is a potent vasodilator with anti-inflammatory and antithrombotic properties, and its diminished bioavailability is a hallmark of hypertensive vascular pathology.

The pathophysiology of endothelial dysfunction in hypertension involves multiple interconnected mechanisms. ROS decrease vascular nitric oxide bioavailability and cause endothelial dysfunction. All of these changes contribute to the structural and functional changes of the vasculature that are associated with the development and perpetuation of hypertension [3]. The primary mechanism involves the uncoupling of endothelial nitric oxide synthase (eNOS), where the enzyme produces superoxide anion instead of NO, creating a vicious cycle of oxidative stress [4]. This uncoupling occurs due to the depletion of essential cofactors, particularly tetrahydrobiopterin (BH4), and the accumulation of asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor.

Oxidative stress serves as a central mediator in hypertensive endothelial dysfunction. Reactive oxygen species (ROS) not only reduce NO bioavailability through direct scavenging but also promote inflammatory cascades, endothelial cell apoptosis, and vascular remodeling. The imbalance between ROS production and antioxidant defense systems leads to endothelial activation, characterized by increased expression of adhesion molecules, pro-inflammatory cytokines, and prothrombotic factors.Traditional therapeutic approaches for hypertension often face limitations including poor bioavailability, off-target effects, and inadequate drug delivery to the vascular endothelium. Given their ability to improve solubility and bioavailability, nanotechnology-based interventions have emerged as promising therapeutic modalities for addressing endothelial dysfunction in hypertension [5]. These nanoparticle-based systems offer several advantages including targeted drug delivery, enhanced cellular uptake, controlled release kinetics, and reduced systemic toxicity.

Nanoparticle-based strategies offer innovative solutions in the management of hypertension by enabling precise drug delivery, minimizing off-target effects, and improving therapeutic efficacy. Dual-targeting approaches—designed to engage specific molecular pathways involved in hypertension—represent a significant advancement in cardiovascular nanomedicine. These systems can be engineered to selectively target endothelial cells, facilitating the localized delivery of therapeutic agents such as antioxidants, nitric oxide (NO) donors, and anti-inflammatory compounds directly to the sites of vascular dysfunction. A variety of nanocarrier platforms have been explored for this purpose, including liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles, each offering unique advantages in terms of drug loading capacity, biocompatibility, and controlled release profiles. These platforms can be functionalized with targeting ligands to enhance endothelial specificity and loaded with therapeutic agents that address the underlying mechanisms of endothelial dysfunction [6]. The potential for personalized medicine approaches using nanotechnology offers hope for more effective management of hypertension and its associated cardiovascular complications.

Endothelial Dysfunction in Hypertension

The Role of the Endothelium

Structure and Physiological Functions of Endothelial Cells

The vascular endothelium is a monolayer of specialized endothelial cells (ECs) lining the inner surface of blood vessels, functioning as a dynamic interface between circulating blood and the vascular wall. These endothelial cells are vital for maintaining vascular homeostasis, regulating vascular tone, permeability, and inflammation, and play a central role in angiogenesis and new vessel formation across various physiological and pathological conditions [7]. These cells exhibit remarkable phenotypic plasticity and heterogeneity, adapting their function to meet the specific demands of different vascular beds.Endothelial cells possess unique structural features that enable their diverse functions. They maintain tight intercellular junctions that regulate vascular permeability, express numerous surface receptors for vasoactive substances, and contain specialized organelles including Weibel-Palade bodies that store von Willebrand factor and other hemostatic proteins. The endothelial surface is covered by a glycocalyx layer that plays crucial roles in mechanotransduction and maintaining the antithrombotic properties of the vessel wall.

Regulation of Vascular Tone and Homeostasis

The endothelium functions as a key regulator of vascular tone by producing several vasoactive mediators, the most critical of which is nitric oxide (NO). Synthesized by endothelial nitric oxide synthase (eNOS), NO induces vasodilation, inhibits platelet aggregation, and reduces leukocyte adhesion, thereby playing a pivotal role in maintaining vascular homeostasis and protecting against atherothrombotic events [8]. An endothelial cells produce prostacyclin (PGI2) and endothelium-derived hyperpolarizing factor (EDHF), which contribute to vascular relaxation.Conversely, the endothelium also produces vasoconstrictor substances including endothelin-1, angiotensin II, and thromboxane A2, maintaining a delicate balance between vasodilation and vasoconstriction. This balance is essential for maintaining adequate tissue perfusion while responding appropriately to physiological demands and pathological challenges.

Mechanisms of Endothelial Dysfunction

Impaired Nitric Oxide (NO) Bioavailability

A hallmark of endothelial dysfunction is the reduced bioavailability of nitric oxide (NO), which arises through several interconnected mechanisms. One major contributor is oxidative stress, where reactive oxygen species (ROS) diminish vascular NO levels by rapidly reacting with it. Specifically, the superoxide anion (O₂⁻) reacts with NO to form peroxynitrite (ONOO⁻), a highly reactive and damaging oxidant. This not only reduces NO availability but also induces cellular damage and further propagates oxidative stress [9]. Additionally, endothelial nitric oxide synthase (eNOS) uncoupling is a critical pathological mechanism. Under conditions where essential cofactors such as tetrahydrobiopterin (BH4) are depleted or when the substrate L-arginine is insufficient, eNOS shifts from producing NO to generating superoxide, thereby exacerbating oxidative imbalance and vascular dysfunction. This uncoupling transforms eNOS from a protective enzyme into a source of reactive oxygen species, creating a vicious cycle of oxidative stress and endothelial dysfunction.

Increased Oxidative Stress and Reactive Oxygen Species (ROS)

Oxidative stress has been strongly implicated in the pathogenesis of CVD, with reactive oxygen species (ROS), via different mechanisms, leading to endothelial cell (EC) dysfunction. A link between oxidative stress and hypertension has been firmly established in multiple animal models of hypertension, with superoxide, hydrogen peroxide, and peroxynitrite being the primary reactive species involved [10].

The major sources of ROS in the hypertensive vasculature include NADPH oxidases, xanthine oxidase, mitochondrial electron transport chain, and uncoupled eNOS. These enzymes become hyperactivated in hypertension, leading to excessive ROS production that overwhelms endogenous antioxidant defenses [11]. The resulting oxidative stress damages endothelial cells, promotes inflammation, and contributes to vascular remodeling.

Inflammatory Activation and Cytokine Release

Endothelial dysfunction is marked by a shift toward a proinflammatory and prothrombotic phenotype, characterized by impaired vasodilation, increased cell proliferation, and vascular inflammation. Activated endothelial cells exhibit upregulated expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and selectins, which promote leukocyte adhesion and transmigration into the vascular wall [12]. This process is driven by activation of the nuclear factor-κB (NF-κB) signaling pathway, leading to the release of pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP). These mediators further exacerbate endothelial damage, perpetuating a vicious cycle of inflammation and vascular dysfunction.

Activation of the Renin-Angiotensin System

The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the regulation of blood pressure, fluid balance, and systemic vascular resistance. In the context of hypertension, overactivation of both systemic and local (tissue-specific) RAAS contributes significantly to endothelial dysfunction and vascular pathology. Angiotensin II, the primary effector molecule of RAAS, promotes vasoconstriction, oxidative stress, inflammation, and endothelial injury. Moreover, it stimulates the production of reactive oxygen species (ROS) via activation of NADPH oxidase and induces the expression of pro-inflammatory cytokines and adhesion molecules. Beyond its acute hemodynamic effects, angiotensin II also contributes to long-term structural changes in the cardiovascular system, including cardiac hypertrophy, vascular smooth muscle cell proliferation, and extracellular matrix remodeling—hallmarks of vascular remodeling and target organ damage in chronic hypertension [13]. Angiotensin II promotes endothelial dysfunction through multiple mechanisms including increased ROS production via NADPH oxidase activation, enhanced inflammatory gene expression, and direct effects on endothelial cell function. The peptide also stimulates aldosterone release, which further contributes to vascular inflammation and fibrosis.

Endothelial Cell Proliferation and Prothrombotic State

Dysfunctional endothelial cells exhibit altered growth characteristics, with increased proliferation and migration contributing to vascular remodeling. The balance between endothelial cell death and regeneration becomes disrupted, leading to areas of endothelial denudation and exposure of the underlying thrombogenic basement membrane [14]. The prothrombotic state is characterized by increased expression of tissue factor, plasminogen activator inhibitor-1 (PAI-1), and von Willebrand factor, while the production of natural anticoagulants such as thrombomodulin and protein S is reduced. This shift promotes thrombosis and contributes to the increased cardiovascular risk associated with hypertension. Figure 1 demonstrates  the endolethial dysfunction and hypertension.

Consequences in Hypertension

Vascular Inflammation and Remodeling

Vascular endothelial dysfunction leads to oxidative stress and inflammation of vessel walls, which in turn enhances vascular endothelial dysfunction. This creates a pathological cycle where inflammation perpetuates endothelial dysfunction, leading to structural changes in the vessel wall including smooth muscle cell proliferation, increased collagen deposition, and arterial stiffening [15]. The inflammatory process involves the recruitment of immune cells, particularly macrophages and T-lymphocytes, which infiltrate the vessel wall and release additional inflammatory mediators. This chronic inflammation contributes to the structural remodeling that characterizes hypertensive vascular disease.

Progression to Atherosclerosis

Atherosclerosis develops as the first step of vascular endothelial dysfunction induced by complex molecular mechanisms. The dysfunctional endothelium becomes permeable to lipoproteins, which accumulate in the vessel wall and undergo oxidative modification. This initiates the formation of foam cells and fatty streaks, the earliest lesions of atherosclerosis [16]. The progression from endothelial dysfunction to atherosclerosis involves the complex interplay of lipid accumulation, inflammation, and thrombosis. The vulnerable atherosclerotic plaque is characterized by a large lipid core, thin fibrous cap, and active inflammation, making it prone to rupture and thrombotic complications.

Increased Cardiovascular Risk

Endothelial dysfunction is a marker of atherosclerosis and contributes to the atherogenic process and the development of atherothrombotic complications. The presence of endothelial dysfunction significantly increases the risk of major cardiovascular events including myocardial infarction, stroke, and cardiovascular death [17]. The increased cardiovascular risk results from multiple factors including impaired coronary flow reserve, increased arterial stiffness, enhanced thrombotic tendency, and accelerated atherosclerosis. These changes collectively contribute to the high morbidity and mortality associated with hypertensive cardiovascular disease, making endothelial dysfunction both a consequence and a driver of cardiovascular risk in hypertension.

Nanotechnology-Based Interventions for Endothelial Dysfunction

Rationale for Nanotechnology in Endothelial Dysfunction

Limitations of Conventional Therapies

Conventional therapeutic approaches for endothelial dysfunction face significant limitations including poor bioavailability, non-specific targeting, and systemic side effects. Traditional pharmacological interventions often fail to achieve optimal therapeutic concentrations at the target site while maintaining systemic tolerability [18]. Additionally, conventional drug delivery systems frequently demonstrate rapid clearance, enzymatic degradation, and inability to cross biological barriers effectively, limiting their therapeutic efficacy in treating vascular disorders [19].

Advantages of Nanocarriers

Nanotechnology offers revolutionary advantages in addressing endothelial dysfunction through targeted delivery systems and enhanced bioavailability. Nanocarriers can be engineered to achieve site-specific delivery, prolonged circulation time, and controlled drug release, thereby maximizing therapeutic efficacy while minimizing systemic toxicity (Farokhzad& Langer, 2009). The ability to modify surface properties enables selective targeting of diseased endothelium, while the nanoscale size facilitates enhanced cellular uptake and intracellular drug accumulation [20].

Types of Nanotechnology Approaches

Nanoparticle-Mediated Drug Delivery

Polymeric nanoparticles, liposomes, and solid lipid nanoparticles represent the most extensively studied drug delivery systems for endothelial dysfunction. These carriers can encapsulate hydrophobic drugs, protect them from degradation, and provide sustained release profiles [21]. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles have demonstrated particular promise in delivering cardiovascular therapeutics due to their biocompatibility and tunable release kinetics [22].

Gene Therapy Using Nucleic Acid-Loaded Nanoparticles

Nanoparticle-mediated gene delivery has emerged as a powerful approach for treating endothelial dysfunction. DNA and RNA-loaded nanoparticles can deliver therapeutic genes encoding nitric oxide synthase, antioxidant enzymes, or anti-inflammatory factors directly to endothelial cells [23]. Cationic lipid nanoparticles and polymer-based carriers have shown efficacy in transfecting endothelial cells both in vitro and in vivo, offering potential for genetic correction of endothelial dysfunction [24].

Antioxidant Enzyme Delivery

Superoxide dismutase (SOD) nanoparticles represent a novel therapeutic approach for combating oxidative stress-induced endothelial dysfunction. Encapsulation of SOD in nanocarriers protects the enzyme from degradation while enabling targeted delivery to sites of oxidative injury [25]. Catalase-loaded nanoparticles have similarly demonstrated protective effects against endothelial damage in experimental models of cardiovascular disease [26].

Peptide- and Ligand-Targeted Nanoparticles

Functionalization of nanoparticles with specific peptides or ligands enables active targeting of endothelial cells. RGD peptides, which recognize integrin receptors overexpressed on activated endothelium, have been successfully employed to direct nanoparticles to sites of vascular injury (Ruoslahti et al., 2010). Similarly, antibody-conjugated nanoparticles targeting endothelial-specific markers such as PECAM-1 or VCAM-1 have shown enhanced accumulation in diseased vasculature [27].

Mechanisms of Action

Restoration of NO Signaling

Nanotechnology-based interventions can restore nitric oxide (NO) bioavailability through multiple mechanisms. Nanocarriers can deliver NO donors, L-arginine, or tetrahydrobiopterin directly to endothelial cells, thereby enhancing endothelial NO synthase activity and NO production [28]. Additionally, nanoparticle-mediated delivery of genes encoding eNOS or its cofactors can provide sustained restoration of NO signaling in dysfunctional endothelium [29]. Figure 2 shows the restoration of endothelial function with nanotechnology.

Reduction of Oxidative Stress and Inflammation

Antioxidant-loaded nanoparticles effectively reduce reactive oxygen species production and inflammatory mediator release in endothelial cells. Nanocarriers can deliver combinations of antioxidants, including vitamin E, vitamin C, and glutathione, providing synergistic protection against oxidative damage [30]. Furthermore, anti-inflammatory agents such as curcumin or resveratrol encapsulated in nanoparticles demonstrate enhanced stability and bioavailability compared to free drugs [31].

Modulation of Endothelial Cell Proliferation and Function

Nanoparticle-based delivery systems can modulate endothelial cell behavior through targeted delivery of growth factors, cytokines, or small molecule regulators. Vascular endothelial growth factor (VEGF) nanoformulations have shown promise in promoting endothelial regeneration and angiogenesis in ischemic tissues [32]. Conversely, anti-angiogenic agents delivered via nanoparticles can prevent pathological neovascularization in diseased tissues [33].

Examples of Preclinical and Clinical Studies

Antihypertensive Drug Nanoformulations

Several preclinical studies have demonstrated the efficacy of nanoparticle-formulated antihypertensive agents. Nifedipine-loaded PLGA nanoparticles showed sustained blood pressure reduction with improved pharmacokinetic profiles compared to conventional formulations [34]. Similarly, enalapril-containing nanoparticles demonstrated enhanced bioavailability and prolonged antihypertensive effects in animal models [35].

Nanoparticle-Based Gene Silencing

RNA interference (RNAi) technology combined with nanoparticle delivery has shown promise in targeting hypertensive pathways. Small interfering RNA (siRNA) directed against angiotensin-converting enzyme delivered via lipid nanoparticles resulted in significant blood pressure reduction in hypertensive animal models [36]. Additionally, microRNA-based therapeutics encapsulated in nanocarriers have demonstrated potential for modulating endothelial function and vascular remodeling[37].

Delivery of Anti-inflammatory Agents

Nanoparticle-mediated delivery of anti-inflammatory compounds has shown efficacy in treating endothelial dysfunction. Prednisolone-loaded nanoparticles targeted to inflamed endothelium demonstrated reduced inflammatory markers and improved vascular function in experimental models of atherosclerosis [38]. Similarly, statins formulated in nanocarriers showed enhanced anti-inflammatory effects on endothelial cells compared to free drugs [39].

Safety and Challenges

Biocompatibility and Toxicity Concerns

The clinical translation of nanotechnology-based interventions faces significant safety challenges. Nanoparticle accumulation in organs such as the liver, spleen, and kidneys raises concerns about long-term toxicity and biocompatibility [40]. Additionally, the potential for nanoparticles to trigger immune responses or inflammatory reactions requires careful evaluation through comprehensive toxicological studies [41].

Regulatory and Ethical Considerations

The regulatory landscape for nanotechnology-based therapeutics remains complex and evolving. Standardization of characterization methods, quality control procedures, and safety assessment protocols poses significant challenges for regulatory approval [42]. Furthermore, ethical considerations regarding the use of nanotechnology in medicine require ongoing dialogue between researchers, clinicians, and regulatory authorities [43].

Translational Hurdles from Bench to Bedside

Despite promising preclinical results, translating nanotechnology-based interventions from laboratory to clinical practice faces numerous obstacles. Scalability of manufacturing processes, batch-to-batch consistency, and cost-effectiveness remain significant challenges [44]. Additionally, the complexity of human pathophysiology compared to animal models may limit the predictive value of preclinical studies, necessitating careful clinical trial design and patient selection [45].

Future Perspectives

Emerging Nanotechnologies and Innovative Delivery Systems

The future of nanotechnology in treating endothelial dysfunction lies in the development of smart, responsive delivery systems that can adapt to physiological conditions. Stimuli-responsive nanoparticles that release therapeutic agents in response to pH changes, temperature variations, or enzymatic activity represent a significant advancement in precision drug delivery [46]. These systems enable temporal and spatial control over drug release, potentially improving therapeutic efficacy while reducing side effects.

Advanced biomimetic nanocarriers, such as cell membrane-coated nanoparticles, are emerging as promising platforms for enhanced biocompatibility and reduced immunogenicity. These systems utilize natural cell membranes from platelets, red blood cells, or endothelial cells to camouflage synthetic nanoparticles, thereby prolonging circulation time and improving targeting specificity [47]. Additionally, exosome-based delivery systems are gaining attention as naturally occurring nanovesicles that can transport therapeutic cargo across biological barriers with minimal toxicity [48].

Nano-robots and intelligent nanodevices equipped with sensing and decision-making capabilities represent the next frontier in nanomedicine. These systems can potentially monitor vascular conditions in real-time, detect early signs of endothelial dysfunction, and autonomously deliver therapeutic interventions [3]. Integration of artificial intelligence with nanotechnology platforms may enable predictive therapeutic responses and adaptive treatment strategies based on individual patient characteristics [6].

Personalized Nanomedicine for Hypertension Management

The concept of personalized nanomedicine is revolutionizing hypertension treatment by tailoring therapeutic interventions to individual patient profiles. Pharmacogenomic approaches combined with nanotechnology enable the development of patient-specific nanocarriers that account for genetic variations in drug metabolism, receptor expression, and disease susceptibility [17]. This personalized approach promises to optimize therapeutic outcomes while minimizing adverse effects.Biomarker-guided nanoparticle design allows for the creation of targeted delivery systems based on specific molecular signatures associated with individual patients’ endothelial dysfunction patterns. Advanced diagnostic nanosensors can identify unique biomarker profiles, enabling clinicians to select appropriate nanoformulations for optimal therapeutic response [18]. This precision medicine approach represents a paradigm shift from the traditional one-size-fits-all treatment strategy.

Companion diagnostics integrated with nanotechnology platforms can provide real-time monitoring of treatment response and enable dose adjustments based on individual patient needs. Theranostic nanoparticles that combine diagnostic imaging capabilities with therapeutic functions allow for simultaneous visualization of drug distribution and assessment of treatment efficacy [19]. This integrated approach facilitates personalized treatment optimization and improves patient outcomes.

Potential for Combinatorial Therapies

The future of nanomedicine in endothelial dysfunction treatment lies in the development of multifunctional nanoplatforms capable of delivering multiple therapeutic agents simultaneously. Combination therapy approaches using nanocarriers can target different pathways involved in endothelial dysfunction, potentially achieving synergistic therapeutic effects [5]. These systems can co-deliver antioxidants, anti-inflammatory agents, and vasoactive compounds to address the multifactorial nature of cardiovascular disease.

Sequential drug delivery systems represent an innovative approach to combinatorial therapy, allowing for temporally controlled release of different therapeutic agents. These systems can be programmed to release drugs in specific sequences based on disease progression or treatment response, optimizing therapeutic efficacy while minimizing drug interactions [16]. Such temporal control is particularly valuable in managing complex cardiovascular conditions requiring multi-step therapeutic interventions.

Nanotechnology-mediated combination of pharmacological and gene therapy approaches offers unprecedented opportunities for comprehensive treatment of endothelial dysfunction. Nanocarriers can simultaneously deliver small molecule drugs and therapeutic genes, enabling both immediate symptomatic relief and long-term genetic correction of underlying pathophysiological mechanisms [14]. This dual-action approach may provide more durable therapeutic benefits compared to single-modality treatments.The integration of nanotechnology with emerging therapeutic modalities, such as immunotherapy and regenerative medicine, presents exciting possibilities for next-generation cardiovascular treatments. Nanoparticle-mediated delivery of stem cells, growth factors, and immunomodulatory agents could potentially restore endothelial function and promote vascular regeneration [11]. These combinatorial approaches may ultimately lead to curative rather than palliative treatments for endothelial dysfunction and related cardiovascular diseases.

Conclusion

Nanotechnology-based interventions represent a transformative approach to treating endothelial dysfunction by addressing key limitations of conventional therapies. The primary mechanisms include targeted drug delivery, enhanced bioavailability, controlled release kinetics, and protection from degradation. These advantages enable precise therapeutic interventions with improved safety profiles through restoration of nitric oxide signaling, reduction of oxidative stress, and modulation of inflammatory responses. The promise extends beyond conventional drug delivery to encompass gene therapy, regenerative medicine, and personalized treatment strategies. Nanoparticle-mediated approaches can deliver antioxidant enzymes, therapeutic genes, and anti-inflammatory agents directly to dysfunctional endothelium, while theranostic platforms integrate diagnostic and therapeutic functions for precision cardiovascular care. Successful clinical translation requires continued research addressing standardization of characterization methods, comprehensive safety profiling, and scalable manufacturing processes. Future priorities include developing next-generation nanocarriers with enhanced targeting specificity, incorporating artificial intelligence for predictive treatment responses, and establishing robust regulatory frameworks for nanotechnology-based therapeutics. The future lies in personalized, multifunctional therapeutic systems capable of addressing individual patient needs. As cardiovascular pathophysiology understanding evolves, nanotechnology platforms will incorporate increasingly sophisticated targeting mechanisms, combination therapies, and real-time monitoring capabilities, ultimately progressing toward curative treatments for endothelial dysfunction and related cardiovascular diseases.

References

• Alvarez-Erviti, L., et al. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29(4), 341-345.
• Anand, P., et al. (2007). Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics, 4(6), 807-818.
• Danhier, F., et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. Journal of Controlled Release, 161(2), 505-522.
• Dobrovolskaia, M. A., & McNeil, S. E. (2007). Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2(8), 469-478.
• Ekins, S., et al. (2019). Exploiting machine learning for end-to-end drug discovery and development. Nature Materials, 18(5), 435-441.
• Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16-20.
• Flaumenhaft, R., & Rifkin, D. B. (2011). The extracellular regulation of growth factor action. Molecular Biology of the Cell, 22(11), 1815-1825.
• Freitas, R. A. (2005). What is nanomedicine? Nanomedicine: Nanotechnology, Biology and Medicine, 1(1), 2-9.
• Gao, X., et al. (2007). In vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotechnology, 25(11), 1165-1170.
• Giljohann, D. A., &Mirkin, C. A. (2009). Drivers of biodiagnostic development. Nature, 462(7272), 461-464.
• Hu, C. M. J., et al. (2011). Nanoparticle biointerfacing by platelet membrane cloaking. Nature, 526(7571), 118-121.
• Jain, S., et al. (2008). Nifedipine loaded PLGA nanoparticles for sustained drug delivery. Drug Development and Industrial Pharmacy, 34(12), 1248-1257.
• Kataoka, K., et al. (2001). Block copolymer micelles for drug delivery: design, characterization and biological significance. Advanced Drug Delivery Reviews, 47(1), 113-131.
• Katakam, P. V., Ujhelyi, M. R., Hoenig, M., & Miller, A. W. (2011). Oxidative stress and endothelial dysfunction in hypertension. Hypertension Research, 34(9), 1039-1048.
• Kelkar, S. S., &Reineke, T. M. (2011). Theranostics: combining imaging and therapy. Bioconjugate Chemistry, 22(10), 1879-1903.
• Lammers, T., et al. (2012). Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release, 161(2), 175-187.
• Lobatto, M. E., et al. (2011). Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nature Reviews Drug Discovery, 10(11), 835-852.
• Lüscher, T. F., & Barton, M. (2008). Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Hypertension, 51(3), 631-640.
• Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377-1397.
• Miller, M. R., et al. (2009). Nitric oxide and vascular function in health and disease. Annals of the New York Academy of Sciences, 1175(1), 96-112.
• Mora-Huertas, C. E., et al. (2010). Nanocapsules: preparation, characterization and drug delivery applications. Current Opinion in Colloid & Interface Science, 15(6), 478-490.
• Mura, S., et al. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991-1003.
• Muzykantov, V. R. (2010). Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opinion on Drug Delivery, 7(4), 403-427.
• Patel, S., et al. (2019). Nanotechnology-based drug delivery systems for enhanced bioavailability. International Journal of Pharmaceutics, 567, 118431.
• Peer, D., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751-760.
• Prabhakaran, M. P., et al. (2011). Electrospunbiocompositenanofibrous scaffolds for neural tissue engineering. Tissue Engineering Part A, 17(7-8), 1049-1058.
• Reddy, M. K., et al. (2006). Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clinical Cancer Research, 12(22), 6677-6686.
• Resnik, D. B., & Tinkle, S. S. (2007). Ethics in nanomedicine. Nanomedicine, 2(3), 345-350.
• Rowe, J. M., Boerma, M., Daniels, J. K., &Alwood, J. S. (2022). Nanoparticle-based therapies in hypertension. Hypertension, 81(1), 15-26.
• Ruoslahti, E., et al. (2010). Targeting of drugs and nanoparticles to tumors. Journal of Cell Biology, 188(6), 759-768.
• Sahoo, S. K., &Labhasetwar, V. (2003). Nanotech approaches to drug delivery and imaging. Drug Discovery Today, 8(24), 1112-1120.
• Sainz, V., et al. (2015). Regulatory aspects on nanomedicines. Biochemical and Biophysical Research Communications, 468(3), 504-510.
• Schulz, E., Jansen, T., Wenzel, P., Daiber, A., &Münzel, T. (2008). Oxidative stress, endothelial dysfunction and cerebrovascular disease. Cerebrovascular Diseases, 25(1-2), 1-8.
• Sengupta, S., et al. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436(7050), 568-572.
• Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215-223.
• Small, E. M., et al. (2010). Regulation of PI3-kinase/Aktsignaling by muscle-enriched microRNA-486. Proceedings of the National Academy of Sciences, 107(9), 4218-4223.
• Soenen, S. J., et al. (2011). Assessing iron oxide nanoparticle toxicity in vitro: current status and future prospects. Nanomedicine, 6(10), 1749-1767.
• Staiculescu, M. C., Foote, C., Meininger, G. A., & Martinez-Lemus, L. A. (2014). The role of reactive oxygen species in microvascular remodeling. International Journal of Molecular Sciences, 15(12), 23792-23835.
• Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A. S., Siasos, G., Tsioufis, C., &Tousoulis, D. (2022). Endothelial dysfunction in hypertension: Current concepts and clinical implications. Frontiers in Medicine, 8, 798958.
• Tian, J., et al. (2007). Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem, 2(1), 129-136.
• Tibbitt, M. W., et al. (2016). Emerging frontiers in drug delivery. Journal of the American Chemical Society, 138(3), 704-717.
• Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery, 13(11), 813-827.
• Venditto, V. J., &Szoka, F. C. (2013). Cancer nanomedicines: so many papers and so few drugs! Advanced Drug Delivery Reviews, 65(1), 80-88.
• Verma, A., et al. (2012). Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nature Materials, 7(7), 588-595.
• Versari, D., Daghini, E., Virdis, A., Ghiadoni, L., &Taddei, S. (2009). Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care, 32(suppl 2), S314-S321.
• Wang, J., et al. (2017). Personalized nanomedicine approach in cancer immunotherapy. Nanotechnology Reviews, 6(5), 505-512.
• Yin, H., et al. (2014). Non-viral vectors for gene-based therapy. Nature Reviews Genetics, 15(8), 541-555.
• Zhao, L., Wang, Y., Liu, J., Wang, K., Guo, X., Ji, B., Wu, W., & Qi, B. (2023). Endothelial dysfunction due to eNOS uncoupling: Molecular mechanisms as potential therapeutic targets. Cellular & Molecular Biology Letters, 28, 21.